Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Shidan Wang(The University of Texas Southwestern Medical Center), Yang Xie(Southwestern Medical Center), Carmen Behrens, Guanghua Xiao(The University of Texas Southwestern Medical Center), Donghan M. Yang(The University of Texas Southwestern Medical Center), Clare Wilhelm(Memorial Sloan Kettering Cancer Center), Lynne D. Berry(Vanderbilt University Medical Center), Ling Cai(The University of Texas Southwestern Medical Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Shirley Yan(The University of Texas Southwestern Medical Center), John D. Minna(Center for Neuro-Oncology), Dara L. Aisner(University of Colorado System), Bruce E. Johnson(Harvard University), Justin A. Bishop(Southwestern Medical Center), Paul A. Bunn(University of Colorado Denver), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Lynette M. Sholl(Brigham and Women's Hospital), David J. Kwiatkowski(Brigham and Women's Hospital), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Ruichen Rong(Southwestern Medical Center)
Cited by 21
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k